Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
4 studies found for:    15972866 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2
Condition: Diabetes Mellitus, Type 1
Interventions: Biological: Otelixizumab;   Biological: Placebo
2 Completed Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Condition: Diabetes Mellitus, Type 1
Interventions: Biological: otelixizumab infusion plus physician determined standard of care;   Biological: placebo infusion plus physician determined standard of care
3 Completed TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)
Condition: Type 1 Diabetes Mellitus
Intervention: Drug: Otelixizumab
4 Completed Extension of Phase II Therapeutic Trial With a Humanized Non-Mitogenic CD3 (ChAgly CD3) Monoclonal Antibody in Recently Diagnosed Type 1 Diabetic Patients
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: ChAgly CD3;   Drug: Placebo

Indicates status has not been verified in more than two years